"10.1371_journal.pone.0036411","plos one","2012-05-04T00:00:00Z","Andrea Giustina; Gherardo Mazziotti; Valter Torri; Maurizio Spinello; Irene Floriani; Shlomo Melmed","Chair of Endocrinology, Department of Medical and Surgical Sciences, University of Brescia, Montichiari Hospital, Brescia, Italy; Department of Medicine, Endocrine Unit, Azienda Ospedaliera Carlo Poma, Mantova, Italy; Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Novartis Farma, Origgio, Varese, Italy; Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, California, United States of America","Conceived and designed the experiments: AG GM SM. Performed the experiments: GM VT IF. Analyzed the data: VT IF. Contributed reagents/materials/analysis tools: MS. Wrote the paper: AG GM SM.","AG is a consultant for Ipsen and Novartis and lecturer for Pfizer and Italfarmaco. GM is a consultant for Novartis and received lecture fees from Ipsen. VT is consultant for Novartis. IF is consultant for Novartis. MS is Novartis Farma employee. SM is a consultant for Novartis and Chiasma, and receives research grants from Novartis, Pfizer and Ipsen. The authors declare that the article is actually concerned with the Novartis product Octreotide. The authors declare that the following authors are consultant for Novartis: AG (also consultant for Ipsen and lecturer for Pfizer and Italfarmaco), GM (also lecturer for Ipsen), VT, IF and SM (consultant also Chiasma, and receives research grants from Pfizer and Ipsen. The authors declare that the above mentioned relationships did not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","05","Andrea Giustina","AG",6,TRUE,3,3,2,3,TRUE,FALSE,FALSE,0,NA,FALSE
